SCHEMBL5080106

SCHEMBL5080106

CONc1nc(C(c2ccccc2)(c2ccccc2)c2ccccc2)nc2c1ncn2C(CCOCP(=O)(O)OC(OC(=O)OC(C)C)OC(=O)OC(C)C)C(OC)OC(c1ccccc1)(c1ccccc1)c1ccccc1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5085976 0.88 HPRT1 (0.32)
SCHEMBL5080082 0.87 CCNB2 (0.31)
SCHEMBL5083016 0.87 CDK5 (0.33)
SCHEMBL5086060 0.86 SERPINA3 (0.32)
SCHEMBL5085999 0.80 CDK1 (0.33)
SCHEMBL5082996 0.80 CDK1 (0.35)
SCHEMBL5083003 0.76 CCNE2 (0.31)
SCHEMBL5086113 0.76 HPRT1 (0.35)
SCHEMBL5080057 0.76 CCNE1 (0.36)
SCHEMBL5082371 0.76 CDK1 (0.33)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7388002-B2 Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases BIOCRYST PHARMACEUTICALS, INC. (US) 2008-06-17 US disclosed
US-20060122391-A1 Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases BIOCRYST PHARMACEUTICALS, INC. (US) 2006-06-08 US disclosed